Effects of the estrous cycle, pregnancy and interferon tau on expression of cyclooxygenase two (COX-2) in ovine endometrium.
In sheep, the uterus produces luteolytic pulses of prostaglandin F2alpha (PGF) on Days 15 to 16 of estrous cycle to regress the corpus luteum (CL). These PGF pulses are produced by the endometrial lumenal epithelium (LE) and superficial ductal glandular epithelium (sGE) in response to binding of pituitary and/or luteal oxytocin to oxytocin receptors (OTR) and liberation of arachidonic acid, the precursor of PGF. Cyclooxygenase-one (COX-1) and COX-2 are rate-limiting enzymes in PGF synthesis, and COX-2 is the major form expressed in ovine endometrium. During pregnancy recognition, interferon tau (IFNtau), produced by the conceptus trophectoderm, acts in a paracrine manner to suppress development of the endometrial epithelial luteolytic mechanism by inhibiting transcription of estrogen receptor alpha (ERalpha) (directly) and OTR (indirectly) genes. Conflicting studies indicate that IFNtau increases, decreases or has no effect on COX-2 expression in bovine and ovine endometrial cells. In Study One, COX-2 mRNA and protein were detected solely in endometrial LE and sGE of both cyclic and pregnant ewes. During the estrous cycle, COX-2 expression increased from Days 10 to 12 and then decreased to Day 16. During early pregnancy, COX-2 expression increased from Days 10 to 12 and remained higher than in cyclic ewes. In Study Two, intrauterine infusion of recombinant ovine IFNtau in cyclic ewes from Days 11 to 16 post-estrus did not affect COX-2 expression in the endometrial epithelium. These results clearly indicate that IFNtau has no effect on expression of the COX-2 gene in the ovine endometrium. Therefore, antiluteolytic effects of IFNtau are to inhibit ERalpha and OTR gene transcription, thereby preventing endometrial production of luteolytic pulses of PGF. Indeed, expression of COX-2 in the endometrial epithelia as well as conceptus is likely to have a beneficial regulatory role in implantation and development of the conceptus.
Kim
Seokwoon
S
Center for Animal Biotechnology and Genomics, Department of Animal Science, 442 Kleberg Center, 2471 TAMU, Texas A&M University, College Station, Texas 77843-2471, USA. swkim@neo.tamu.edu
Choi
Youngsok
Y
Spencer
Thomas E
TE
Bazer
Fuller W
FW
D000818:Animals; D051546:Cyclooxygenase 2; D015237:Dinoprost / Q000096:biosynthesis; D010064:Embryo Implantation / Q000187:drug effects / Q000502:physiology; D004717:Endometrium / Q000187:drug effects / Q000201:enzymology*; D004790:Enzyme Induction / Q000187:drug effects; D004847:Epithelial Cells / Q000378:metabolism; D047628:Estrogen Receptor alpha; D030762:Estrous Cycle / Q000502:physiology*; D005260:Female; D005786:Gene Expression Regulation / Q000187:drug effects; D007370:Interferon Type I / Q000494:pharmacology* / Q000502:physiology; D007527:Isoenzymes / Q000096:biosynthesis* / Q000235:genetics; D003341:Luteolysis / Q000502:physiology; D011247:Pregnancy; D011257:Pregnancy Proteins / Q000494:pharmacology* / Q000502:physiology; D011270:Pregnancy, Animal / Q000502:physiology*; D011451:Prostaglandin-Endoperoxide Synthases / Q000096:biosynthesis* / Q000235:genetics; D012333:RNA, Messenger / Q000096:biosynthesis; D011960:Receptors, Estrogen / Q000096:biosynthesis / Q000235:genetics; D018045:Receptors, Oxytocin / Q000096:biosynthesis / Q000235:genetics; D011994:Recombinant Proteins / Q000494:pharmacology; D012756:Sheep / Q000502:physiology*
D047628:Estrogen Receptor alpha; D007370:Interferon Type I; D007527:Isoenzymes; D011257:Pregnancy Proteins; D012333:RNA, Messenger; D011960:Receptors, Estrogen; D018045:Receptors, Oxytocin; D011994:Recombinant Proteins; C020947:interferon tau; D015237:Dinoprost; D051546:Cyclooxygenase 2; D011451:Prostaglandin-Endoperoxide Synthases